Galapagos: Positive news for Galapagos with GSK entering phase II with another JAK1

BUY, Fair Value EUR22.5 vs. EUR21.5 (+25%)

News published on February Wednesday 6, 2013
Share on

When the Galapagos share was suspended in the middle of trading, we, like many investors, imagined a number of scenarios. The news announced was definitely not on the list but it is bottom line positive news. GSK announced the start of phase II studies with a JAK1 compound called GSK2586184 in two indications: systemic lupus erythematosus (SLE) and chronic plaque psoriasis. We have increased our probability of success for this project to 20% and raised our Fair Value to EUR22.5.

Full report available to subscribers
Please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities